Alimera Sciences Inc. (ALIM)
5.54
-0.01 (-0.18%)
At close: Sep 13, 2024, 8:00 PM
-0.18% (1D)
| Bid | n/a |
| Market Cap | 301.29M |
| Revenue (ttm) | 99.68M |
| Net Income (ttm) | -14.7M |
| EPS (ttm) | 1.05 |
| PE Ratio (ttm) | 5.276190476190476 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | n/a |
| Volume | 2,677,974 |
| Avg. Volume (20D) | 866,825 |
| Open | 5.55 |
| Previous Close | 5.55 |
| Day's Range | 5.53 - 5.56 |
| 52-Week Range | 2.61 - 5.65 |
| Beta | 1.25 |
About ALIM
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affectin...
Sector Healthcare
IPO Date Nov 4, 2019
Employees 154
Stock Exchange NASDAQ
Ticker Symbol ALIM
Website https://alimerasciences.com
Analyst Forecast
According to 3 analyst ratings, the average rating for ALIM stock is "Hold." The 12-month stock price forecast is $6, which is an increase of 8.30% from the latest price.
Stock Forecasts7 months ago
-6.49%
Alimera Sciences shares are trading lower after th...
Unlock content with
Pro Subscription
10 months ago
+75.87%
Alimera Sciences shares are trading higher after the company announced that signed a definitive agreement to be acquired by ANI Pharmaceuticals.